Under the agreement, ProBioGen will integrate some of Boehringer’s technologies to accommodate a seamless process and technology transfer from pilot and medium-scale to commercial-scale production capacities.
ProBioGen’s clients will thereby gain access to Boehringer’s manufacturing technology platform and large-scale commercial production. In addition, Boehringer’s clients and partners will benefit from ProBioGen’s expertise in process development and manufacturing.
Michael Schlenk, CEO of ProBioGen, said: “ProBioGen’s strategic production alliance with Boehringer Ingelheim is an important milestone in our commercial strategy. For one, our clients will gain access to one of the leading commercial-scale production platforms, but we will also be able to expand our client base and have started to build additional production capabilities to meet increased client demand.”